Viridian Therapeutics (VRDN) remains a 'Sell' as both lead TED assets underperform versus Amgen’s Tepezza, with limited ...
Phase 2 RECLAIM topline data in alcohol use disorder, Phase 3 MASH plans for 2026, cash runway to 2028 and dilution ...
The 49ers have added some depth to their defensive line.
Versatile veteran Cam Sample joins the 49ers, adding durable "big end" presence and schematic flexibility to bolster the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results